SAAmplify™ αSYN: A New Era in Parkinson's & Lewy Body Diagnosis

The Diagnostic Challenge

Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders characterized by misfolded alpha-synuclein protein aggregates in the brain-pathological clumps that historically could only be confirmed at autopsy. Clinicians have long struggled to accurately diagnose these "synucleinopathies" during life based on symptoms alone.

Even with modern criteria, an estimated 20–30% of PD and Lewy body dementia diagnoses made during life turn out to be incorrect when verified against autopsy findings. This diagnostic uncertainty can leave patients in a protracted "diagnostic odyssey," averaging 2–3 years of consultations and tests, sometimes receiving inappropriate treatments.

How SAAmplify™ αSYN Works

SAAmplify-αSYN is based on a seed-amplification assay (SAA) technique, which exploits the prion-like behavior of misfolded α-synuclein to amplify and detect even minute amounts of pathological protein. The assay essentially mimics what happens in the brain during disease: misfolded α-synuclein "seeds" induce normal α-synuclein to misfold and aggregate.

The Seed Amplification Process

Clinical Impact: Why It Matters

• Diagnostic Certainty: Moves from "we suspect" to "we have detected"-providing empirical evidence of misfolded α-synuclein previously only attainable at autopsy.
• Earlier Detection: Identifies α-synuclein pathology up to 10 years before clinical diagnosis-even in patients with no motor symptoms.
• Differential Diagnosis: Distinguishes synucleinopathies from Alzheimer's, tauopathies, and other conditions presenting with similar symptoms.
• Clinical Trial Enrichment: Ensures participants in PD drug trials truly have underlying α-synuclein pathology-improving outcomes and accelerating treatment development.

Earlier detection means earlier intervention, giving patients a better chance at improved outcomes and quality of life.

- Amprion / Mayo Clinic Laboratories Partnership Announcement

Performance Data

The SAAmplify-αSYN assay has been rigorously evaluated in multiple studies and clinical cohorts, demonstrating impressive accuracy that rivals many gold-standard clinical tests.

Validated Performance Metrics

Metric	Value
Overall Sensitivity (α-synucleinopathies)	96%
DLB Sensitivity (Cognitive Impairment Study)	95.7%
Overall Specificity	92%
DLB Specificity (Cognitive Impairment Study)	93.2%
Overall Diagnostic Accuracy	~94%

The assay proves its value in early and prodromal disease settings. Patients with isolated REM sleep behavior disorder or anosmia who are at high risk for PD have shown positive α-syn seed amplification results years in advance of motor symptoms-all individuals who eventually developed PD had positive seeding results 1–10 years before formal diagnosis.

What It Takes to Run the Test

Test Requirements Overview

• Sample Requirements: ~1 mL CSF (0.5 mL acceptable, 0.3 mL minimum) • Clear, blood-free • Collected in sterile polypropylene tube • Frozen and shipped on dry ice
• Key Reagents: Highly purified recombinant human α-synuclein (substrate) • Thioflavin T fluorescent dye • Optimized buffer solutions • Strict contamination controls
• Equipment: Fluorescence plate reader with incubating shaker • Multi-well plates • Temperature control (~37°C) • Real-time fluorescence monitoring capability
• Turnaround Time: ~15 days from sample receipt to result • Assay runs for 5-7 days with repeat cycles • Batched high-throughput operations available

To ensure assay consistency, laboratories rely on high-quality biological matrices and control materials for assay validation, calibration, and ongoing quality assurance. Human CSF samples, both normal and disease-state, are crucial for generating accurate positive and negative controls. These are often sourced from biobanks or specialized providers who can ensure standardized collection, screening, and documentation.

Future Potential

The successful deployment of SAAmplify-αSYN heralds a new era for neurodegenerative disease diagnostics, and its impact is likely to grow significantly in the coming years.

Emerging Horizons

• Alternative Biofluids: Blood-based SAA has detected PD up to a decade before symptoms with 100% accuracy in early studies. Skin biopsy approaches also under development.
• Quantitative Metrics: Kinetic signatures (lag time, aggregation rate, peak fluorescence) may correlate with disease subtype and progression rate for prognostic value.
• Extended Platform: SAA technology being adapted for tau (Alzheimer's), TDP-43 (ALS), and prions-toward a comprehensive panel for major neurodegenerative pathologies.
• FDA Support: FDA has issued a "Letter of Support" for α-synuclein SAA technology as a tool to advance drug development and diagnostics.

We have the real possibility to impact the lives of millions if we can identify the disease before it damages the brain.

- Dr. Claudio Soto, PhD, CSO of Amprion

Conclusion

SAAmplify™ αSYN represents a transformative advancement in the diagnosis of Parkinson's disease, Lewy body dementia, and related synucleinopathies. By detecting the telltale misfolded α-synuclein seeds in a patient's CSF, it gives clinicians a window into the brain's pathology without waiting for an autopsy.

The assay's high sensitivity, specificity, and ability to detect disease in prodromal stages address a long-standing unmet need in neurology-the need for objective, biologically based diagnostics. For patients, this means more timely and accurate answers about their condition, and consequently, more tailored treatment and planning.

Seed-amplification assays like SAAmplify-αSYN are charting a new course for how we approach neurodegenerative diseases: with precision diagnostics leading the way for precision medicine. The hope is that as this technology continues to evolve, the next generation of patients will receive diagnoses and interventions guided by the actual proteins driving their disease-heralding a future where neurodegenerative disorders are detected earlier, differentiated more accurately, and ultimately treated more effectively.

References

1. Giannakis, A., et al. Seed Amplification Assay for α-Synuclein: Diagnostic Applications in Synucleinopathies. Int J Mol Sci. 2025. PubMed
2. Mayo Clinic Laboratories & Amprion Press Release: Collaboration to Advance Neurodegenerative Disease Diagnostics. March 26, 2025. Mayo Clinic Labs News
3. Amprion Diagnostics The Amprion Answer: α-synuclein. 2025. Amprion Website
4. Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: A meta-analysis. Neurology. 2016;86(6):566-576. PubMed
5. Rizzo, G. et al. Accuracy of clinical diagnosis of dementia with Lewy bodies: A meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(4):358-366. PubMed
6. Esteller-Gauxax, D. et al. α-Synuclein Seed Amplification Assay in a Cohort With Cognitive Impairment. Neurology. 2025;105(7):e214040. PubMed
7. Mayo Clinic Laboratories Test Catalog: Alpha-Synuclein Protein Aggregates, CSF (Test ID: ASYNC). 2025. Mayo Clinic Labs
8. Kiani, L. In Brief: Blood test for early Parkinson disease diagnosis. Nat Rev Neurol. 2024;20:316. Nature
9. Parkinson's News Today (M. Maia, PhD) "Amprion launching SAAmplify as tool to help in disease diagnosis." Aug 1, 2024. Parkinson's News Today
10. Verdurand, M. et al. Toward alpha-synuclein seed amplification assay in clinical practice. Mov Disord. 2023. PubMed (PMC11736632)
11. Veritas Innovation Company Website, 2025. High-quality human biological matrices for diagnostic assay development. Veritas Innovation
12. Soto, C. (Claudio Soto, PhD, CSO of Amprion) Quoted on Amprion website, 2025. Amprion Website